- Home
- FTFT vs CYCC Comparison
FTFT vs CYCC Comparison
Compare FTFT & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTFT
- CYCC
- Stock Information
- Founded
- FTFT N/A
- CYCC 1992
- Country
- FTFT United States
- CYCC United States
- Employees
- FTFT N/A
- CYCC N/A
- Industry
- FTFT Business Services
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- FTFT Consumer Discretionary
- CYCC Health Care
- Exchange
- FTFT Nasdaq
- CYCC Nasdaq
- Market Cap
- FTFT 3.9M
- CYCC 3.6M
- IPO Year
- FTFT N/A
- CYCC N/A
- Fundamental
- Price
- FTFT $0.14
- CYCC $0.25
- Analyst Decision
- FTFT
- CYCC Strong Buy
- Analyst Count
- FTFT 0
- CYCC 1
- Target Price
- FTFT N/A
- CYCC $11.00
- AVG Volume (30 Days)
- FTFT 638.3K
- CYCC 160.2K
- Earning Date
- FTFT 05-19-2025
- CYCC 05-13-2025
- Dividend Yield
- FTFT N/A
- CYCC N/A
- EPS Growth
- FTFT N/A
- CYCC N/A
- EPS
- FTFT N/A
- CYCC N/A
- Revenue
- FTFT $18,543,659.00
- CYCC $74,000.00
- Revenue This Year
- FTFT N/A
- CYCC N/A
- Revenue Next Year
- FTFT N/A
- CYCC $88.68
- P/E Ratio
- FTFT N/A
- CYCC N/A
- Revenue Growth
- FTFT N/A
- CYCC N/A
- 52 Week Low
- FTFT $0.13
- CYCC $0.22
- 52 Week High
- FTFT $0.95
- CYCC $4.00
- Technical
- Relative Strength Index (RSI)
- FTFT 22.77
- CYCC 29.30
- Support Level
- FTFT $0.18
- CYCC $0.29
- Resistance Level
- FTFT $0.25
- CYCC $0.32
- Average True Range (ATR)
- FTFT 0.02
- CYCC 0.02
- MACD
- FTFT -0.00
- CYCC -0.00
- Stochastic Oscillator
- FTFT 8.85
- CYCC 19.92
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and cryptocurrency mining farm in the U.S. The company's reportable segments include the Supply chain financing/trading segment which generates key revenue, and the Asset management service segment.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.